You are currently viewing Johns Hopkins University: Inhibitor Drug Entinostat ‘Primes’ the Body to Better Respond to Anti-Cancer Treatment with Immunotherapy

Johns Hopkins University: Inhibitor Drug Entinostat ‘Primes’ the Body to Better Respond to Anti-Cancer Treatment with Immunotherapy

  • Post author:
  • Post category:Uncategorized

Combining a histone deacetylase inhibitor drug with immunotherapy agents is safe, and may benefit some patients with advanced cancers that have not responded to traditional therapy, according to results of a phase 1 clinical trial led by researchers at the Johns Hopkins Kimmel Cancer Center, Bloomberg~Kimmel Institute for Cancer Immunotherapy and several other centers including […]